Finance

Lists
1276:HKG
Jiangsu Hengrui Pharmaceuticals Co Ltd
47,60 HKD
-0,83%
(-0,40) 1D
16-окт., 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 1276...
Open
48,00 HKD
High
49,30 HKD
Low
46,92 HKD
Mkt. cap
345,69 млд
Avg. vol.
4,04 млн
Volume
4,16 млн
P/E ratio
34,86
52-wk high
84,50 HKD
52-wk low
43,02 HKD
EPS
1,37 HKD
No. of employees
21 миң
Open
48,00 HKD
High
49,30 HKD
Low
46,92 HKD
Mkt. cap
345,69 млд
Avg. vol.
4,04 млн
Volume
4,16 млн
P/E ratio
34,86
52-wk high
84,50 HKD
52-wk low
43,02 HKD
EPS
1,37 HKD
No. of employees
21 миң
News stories
From web sources and news partners
Profile
Jiangsu Hengrui Pharmaceuticals Company Ltd., also known as Jiangsu Hengrui, is a Chinese pharmaceutical company that manufactures and distributes various types of drug packaging materials, cancer-treating antineoplastics, cardiovascular medication, painkillers, antibiotics, and related products. It is the largest listed pharmaceutical company in China. Wikipedia
About Jiangsu Hengrui Pharmaceuticals Co Ltd
CEO-
Employees20,7 миң
Founded1970
Headquarters-
SectorPharmaceutical industry
Next call 9 күндөн кийин
27-окт., шейш., 09:00
Fiscal period
Q3 2026
- / 0,31 CN¥
Revenue / Est. (CNY)
- / 9,17 млд
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
7,43 млд
8,44 млд
8,14 млд
7,32 млд
Cost of goods sold
1,07 млд
1,25 млд
1,09 млд
1,02 млд
Cost of revenue
1,07 млд
1,25 млд
1,09 млд
1,02 млд
Research and development expenses
1,72 млд
2,02 млд
1,65 млд
1,84 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,23 млд
3,01 млд
2,81 млд
2,78 млд
Operating expense
4,76 млд
5,35 млд
4,48 млд
4,61 млд
Total operating expenses
5,83 млд
6,60 млд
5,57 млд
5,63 млд
Operating income
1,60 млд
1,84 млд
2,57 млд
1,68 млд
Other non operating income
-154,21 млн
145,74 млн
-345,12 млн
243,91 млн
EBT including unusual items
1,36 млд
2,30 млд
2,56 млд
2,40 млд
EBT excluding unusual items
1,68 млд
1,91 млд
2,55 млд
1,60 млд
Income tax expense
55,51 млн
338,85 млн
275,87 млн
211,27 млн
Effective tax rate
4,08%
14,76%
10,79%
8,82%
Other operating expenses
-217,30 млн
326,84 млн
4,76 млн
-5,09 млн
Net income
1,30 млд
1,96 млд
2,28 млд
2,18 млд
Net profit margin
17,52%
23,22%
28,04%
29,84%
Earnings per share
0,20
-
-
-
Interest and investment income
242,14 млн
288,66 млн
322,96 млн
448,28 миң
Interest expense
-689,68 миң
-2,00 млн
-448,28 миң
-322,96 млн
Net interest expenses
241,45 млн
286,66 млн
322,52 млн
-322,52 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
1,78 млд
2,04 млд
2,77 млд
1,93 млд
Gain or loss from assets sale
2,31 млн
-4,05 млн
-
-40,62 млн
AI content may include mistakes. Learn more
Google колдонмолору